AI Chip to Help Capture and Analyze Molecular Data in RT
By LabMedica International staff writers Posted on 28 Nov 2017 |
Image: The system-on-chip is designed to yield highly-secure molecular data, which can be used in the recognition and analysis of health threats caused by pathogens and other living organisms (Photo courtesy of Nano Global).
Molecular data company Nano Global (Austin, TX, USA) is developing a chip using intellectual property (IP) from Arm Holdings (Cambridge, UK), a semiconductor IP company, to help redefine how global health challenges ranging from superbugs to infectious diseases, and cancer are conquered. The pioneering system-on-chip (SoC) will yield highly-secure molecular data, which can be used in the recognition and analysis of health threats caused by pathogens and other living organisms.
The chip, combined with the company's scientific technology platform, leverages advances in nanotechnology, optics, artificial intelligence (AI), blockchain authentication, and edge computing to access and analyze molecular-level data in real time. The initial development of the chip is underway and the first delivery is expected by 2020, with the company having already begun adding new partners to their platform.
"In partnership with Arm, we're tackling the vast frontier of molecular data to unlock the unlimited potential of this universe," said Steve Papermaster, Chairman and CEO of Nano Global. "The data our technology can acquire and process will enable us to create a safer and healthier world."
"We believe the technology Nano Global is delivering will be an important step forward in the collective pursuit of care that improves lives through the application of technology," said Rene Haas, executive vice president and president of IPG, Arm. "By collaborating with Nano Global, Arm is taking an active role in developing and deploying the technologies that will move us one step closer to solving complex health challenges."
Nano Global will also be partnering with several leading institutions, including Baylor College of Medicine and National University of Singapore, on broad research initiatives in clinical, laboratory, and population health environments to accelerate data collection, analysis, and product development.
Related Links:
Nano Global
Arm Holdings
The chip, combined with the company's scientific technology platform, leverages advances in nanotechnology, optics, artificial intelligence (AI), blockchain authentication, and edge computing to access and analyze molecular-level data in real time. The initial development of the chip is underway and the first delivery is expected by 2020, with the company having already begun adding new partners to their platform.
"In partnership with Arm, we're tackling the vast frontier of molecular data to unlock the unlimited potential of this universe," said Steve Papermaster, Chairman and CEO of Nano Global. "The data our technology can acquire and process will enable us to create a safer and healthier world."
"We believe the technology Nano Global is delivering will be an important step forward in the collective pursuit of care that improves lives through the application of technology," said Rene Haas, executive vice president and president of IPG, Arm. "By collaborating with Nano Global, Arm is taking an active role in developing and deploying the technologies that will move us one step closer to solving complex health challenges."
Nano Global will also be partnering with several leading institutions, including Baylor College of Medicine and National University of Singapore, on broad research initiatives in clinical, laboratory, and population health environments to accelerate data collection, analysis, and product development.
Related Links:
Nano Global
Arm Holdings
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics